After seed: What happened next to Europe’s women’s health startups?

We followed 36 European women’s health companies after their early-stage funding to explore how many reached Series A, what happened to the rest and how their experience fits into the wider market.

I’ve heard a similar question from several angel investors in women’s health recently: where are all the Series A rounds?

It’s a fair question. We hear about women’s health startups securing their first investments, but much less about what happens to them afterwards. How many go on to raise further funding, and how many make it to Series A?

I wanted to understand what was actually happening. So I went back to 36 European women’s health companies with qualifying pre-seed or seed financing between 2022 and 2024 and followed their funding and publicly visible progress through to mid-September 2026.

I started with Europe, where there’s less research tracking what happens to women’s health companies beyond their early rounds.

Of the 36 companies, just one had gone on to reach Series A.

So what’s going on? Is women’s health struggling more than the wider European market? What happened to all of these companies?

Let’s find out…..